Blockchain Registration Transaction Record

SureNano Science Advances GEP-44 Toward Clinical Trials with LabCorp

SureNano Science initiates FDA IND-enabling GLP toxicology program for GEP-44 with LabCorp, advancing GLP-1 agonist peptide for obesity and diabetes, and expands investor outreach via IBN.

This news matters because it signals SureNano's transition from a surfactant distributor to a serious player in the obesity and diabetes drug market, a sector valued at over $100 billion. If GEP-44 succeeds in clinical trials, it could offer a more tolerable and potentially non-injectable alternative to current GLP-1 drugs like Ozempic, expanding treatment options for millions of patients. The company's strategic partnerships also enhance its visibility, potentially driving investment and accelerating development.